Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 2
2019 1
2022 1
2023 1
2024 6
2025 8
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
The DEBBRAH trial: Trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with leptomeningeal carcinomatosis.
Vaz Batista M, Pérez-García JM, Garrigós L, García-Sáenz JÁ, Cortez P, Racca F, Blanch S, Ruiz-Borrego M, Fernández-Ortega A, Fernández-Abad M, Iranzo V, Gion M, Martrat G, Alcalá-López D, Pérez-Escuredo J, Sampayo-Cordero M, Llombart-Cussac A, Braga S, Cortés J. Vaz Batista M, et al. Among authors: alcala lopez d. Med. 2025 Jan 10;6(1):100502. doi: 10.1016/j.medj.2024.08.001. Epub 2024 Sep 11. Med. 2025. PMID: 39265579 Free article. Clinical Trial.
3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.
Pérez-García JM, Cortés J, Ruiz-Borrego M, Colleoni M, Stradella A, Bermejo B, Dalenc F, Escrivá-de-Romaní S, Calvo Martínez L, Ribelles N, Marmé F, Cortés A, Albacar C, Gebhart G, Prat A, Kerrou K, Schmid P, Braga S, Di Cosimo S, Gion M, Antonarelli G, Popa C, Szostak E, Alcalá-López D, Gener P, Rodríguez-Morató J, Mina L, Sampayo-Cordero M, Llombart-Cussac A; PHERGain Trial Investigators. Pérez-García JM, et al. Among authors: alcala lopez d. Lancet. 2024 Apr 27;403(10437):1649-1659. doi: 10.1016/S0140-6736(24)00054-0. Epub 2024 Apr 3. Lancet. 2024. PMID: 38582092 Clinical Trial.
Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trial.
Remon J, Bironzo P, Girard N, Bigay-Game L, Juan-Vidal O, de Castro J, Reguart N, Greillier L, Cousin S, Dansin E, Majem M, Bernabé R, Mosquera Martinez J, Díaz M, Meya A, Alcalá-López D, García-Sanz A, Righi L, Novello S, Besse B. Remon J, et al. Among authors: alcala lopez d. Lancet Oncol. 2025 Sep;26(9):1215-1226. doi: 10.1016/S1470-2045(25)00300-6. Lancet Oncol. 2025. PMID: 40907517 Clinical Trial.
Brain-wide representation of social knowledge.
Alcalá-López D, Mei N, Margolles P, Soto D. Alcalá-López D, et al. Soc Cogn Affect Neurosci. 2024 Jun 12;19(1):nsae032. doi: 10.1093/scan/nsae032. Soc Cogn Affect Neurosci. 2024. PMID: 38804694 Free PMC article.
Lurbinectedin Plus Pembrolizumab in Relapsed SCLC: The Phase I/II LUPER Study.
Calles A, Navarro A, Doger de Speville Uribe BG, Colomé EÁ, de Miguel M, Álvarez R, Arregui M, Moreno V, Rocha P, Calvo E, Ramon-Patino J, Corral de la Fuente E, Alcalá-López D, Boix O, Fernández-Pinto M, Rodríguez-Morató J, Palmero R, Nadal E, Jove M, Felip E. Calles A, et al. Among authors: alcala lopez d. J Thorac Oncol. 2025 Jul;20(7):969-982. doi: 10.1016/j.jtho.2025.02.005. Epub 2025 Feb 10. J Thorac Oncol. 2025. PMID: 39938593 Free article. Clinical Trial.
Ipatasertib combined with non-taxane chemotherapy for patients with previously treated advanced triple-negative breast cancer: the PATHFINDER phase IIa trial.
López-Miranda E, Pérez-García JM, Gión M, Ribelles N, Cortez-Castedo P, Alonso-Romero JL, García MM, González-Santiago S, Bermejo B, Morales S, Carañana V, Garrigós L, Fernández-Pinto M, García-Vicente S, Garcia-Sanz A, Mena-Molina A, Boix O, Alcalá-López D, Llombart-Cussac A, Cortés J. López-Miranda E, et al. Among authors: alcala lopez d. Breast Cancer Res. 2025 Aug 6;27(1):141. doi: 10.1186/s13058-025-02089-4. Breast Cancer Res. 2025. PMID: 40770648 Free PMC article. Clinical Trial.
Liposomal irinotecan in patients with HER2-negative breast cancer and brain metastases: The PHENOMENAL phase 2 study.
Borrego MR, López-Bravo DP, Vila MM, Pérez-García JM, Fernández M, Tormo SB, García-Saenz JÁ, Lema L, Garau I, Cortez P, Torres AA, Conejo EA, Calvo I, Ferrer N, Blancas I, Amillano K, Santasusagna S, Benderra MA, Alcalá-López D, Antonarelli G, Sampayo-Cordero M, Llombart-Cussac A, Cortés J. Borrego MR, et al. Among authors: alcala lopez d. Eur J Cancer. 2026 Jan 17;233:116161. doi: 10.1016/j.ejca.2025.116161. Epub 2025 Dec 4. Eur J Cancer. 2026. PMID: 41371050 Clinical Trial.
Second-Line Endocrine Therapy With or Without Palbociclib Rechallenge in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: PALMIRA Trial.
Llombart-Cussac A, Harper-Wynne C, Perelló A, Hennequin A, Fernández-Ortega A, Colleoni M, Marín S, Quiroga V, Medioni J, Iranzo V, Wheatley D, Del Barco Berrón S, Antón A, Dobi E, Ruiz-Borrego M, Alcalá-López D, Pérez-Escuredo J, Antonarelli G, Sampayo-Cordero M, Pérez-García JM, Cortés J. Llombart-Cussac A, et al. Among authors: alcala lopez d. J Clin Oncol. 2025 Jun 20;43(18):2084-2093. doi: 10.1200/JCO-24-01865. Epub 2025 Apr 28. J Clin Oncol. 2025. PMID: 40294349 Free PMC article. Clinical Trial.
Computing the Social Brain Connectome Across Systems and States.
Alcalá-López D, Smallwood J, Jefferies E, Van Overwalle F, Vogeley K, Mars RB, Turetsky BI, Laird AR, Fox PT, Eickhoff SB, Bzdok D. Alcalá-López D, et al. Cereb Cortex. 2018 Jul 1;28(7):2207-2232. doi: 10.1093/cercor/bhx121. Cereb Cortex. 2018. PMID: 28521007 Free article.
16 results